drugset / Trial / NCT00722046
Multiple IV Dose Study Of PF-04360365 In Patients With Mild To Moderate Alzheimer's Disease
RandomizedParallel-groupTriple-blindTreatment
Summary
Purpose of the study is to determine whether multiple dose administration of PF-04360365 is safe and well tolerated in patient with mild to moderate Alzheimer's disease.
Timeline
- Start
- 2008-12-05
- Primary completion
- 2011-08-16
- Completion
- 2011-08-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ponezumab | Monoclonal antibody | 0.1 mg/kg | Intravenous |
| Subject | Ponezumab | Monoclonal antibody | 0.5 mg/kg | Intravenous |
| Subject | Ponezumab | Monoclonal antibody | 1 mg/kg | Intravenous |
| Subject | Ponezumab | Monoclonal antibody | 3 mg/kg | Intravenous |
| Subject | Ponezumab | Monoclonal antibody | 8.5 mg/kg | Intravenous |